Needham, Mass. (PRWEB) May 16, 2013
Cambridge Healthtech Institute will host its fifth annual The Bioprocessing Summit from August 19-23, 2013 at the Renaissance Waterfront Hotel in Boston, MA. The ten meetings comprising the Summit provide a close-up look at the current strategies and innovations for optimizing bioprocesses while mitigating risk and ensuring bottom-line quality. Leaders in the field will reveal how their work has resulted in innovative ways to produce biopharmaceuticals with greater specificity and efficiency.
“In this age of rapid innovation, it's critical to keep up with advances and trends, and to exchange ideas with international colleagues. This event is designed to provide insights that optimize tasks at the bench with an emphasis on 'real-world' experience,” says Mary Ruberry, Conference Director of Cambridge Healthtech Institute.
The 2013 Bioprocessing Summit features an expanded roster of meetings. Along with the upstream mainstays of cell culture and cell line development, the Summit now has an expanded formulation foci, plus new meetings delving into early IND strategies. Biomanufacturing and integrating disposables will be explored through the inaugural "Facilities for Manufacturing Biologics" meeting, and the 3rd annual "Scaling Up & Down with Optimized Bioreactors + Disposables" meeting will investigate small-scale models, issues of scale and single-use technologies.
Attendees will hear keynote presentations from Thomas Ryll of Biogen Idec, R. Thomas Warf of BARDA, Palani Palaniappan of Millennium: The Takeda Oncology Company, Florian M. Wurm of EPFL/ExcellGene SA, Ravinder Bhatia of Janssen Research & Development, Jianmei Kochling of Genzyme, a Sanofi company, Donna L. Luisi of Pfizer, Thomas Laue of University of New Hampshire, and Joanne Beck of Shire Human Genetic Therapies.
There are plenty of other highlights as we
Copyright©2012 Vocus, Inc.
All rights reserved